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Evidence-based management of patients with acute non-variceal upper
gastrointestinal bleeding
James Y.W. Lau*
a b s t r a c t
The management of patients with acute upper gastrointestinal bleeding should consist of early assessment and volume resuscitation. Endoscopy should
be performed in all patients within 24 hours of their presentation. The Glasgow Blatchford score requires validation in different centers. It is accurate in
identifying those at low risk of requiring intervention. The risk score is less speciﬁc in identifying those who require urgent endoscopic intervention.
During endoscopy, the presence of active bleeding and a non-bleeding visible vessel mandate endoscopic hemostatic treatment. There is also evidence
that clots overlying ulcers should be unveiled and hemostatic treatment offered to underlying stigmata. Injection therapy using diluted epinephrine alone
is considered inadequate. A second treatment should be added to induce thrombosis of the bleeding artery. The use of thermo-coagulation with a thermal
device or hemo-clips alone or after pre-injection with epinephrine is equally efﬁcacious. Second look endoscopy should be performed in selected high risk
or re-bleeding patients. Proton pump inhibitor (PPI) should administer as an adjunctive therapy. The dose of PPI use continues to be controversial.
Angiographic embolization compares favorably to surgery as a rescue therapy where endoscopic therapy fails. Helicobacter pylori should be tested and
treated in the presence of infection. In those who require aspirin for cardiovascular prophylaxis, aspirin should be resumed early. A low dose PPI should be
added for secondary prophylaxis. In those who continue to require an analgesic, co-therapy of PPI with traditional non-steroidal anti-inﬂammatory agent
and the use of COX-II inhibitor alone are associated with a small risk of recurrent bleeding. A combination of COX-II inhibitor and PPI is preferred in those
with very high risk of gastrointestinal events. In patients on dual antiplatelet agents, PPI appears to reduce gastrointestinal events without increasing
cardiovascular events.
Copyright  2012, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Acute upper gastrointestinal bleeding (AUGIB) is a common
medical emergency. In the UK, its incidence is between 80 and 110
per 100,000 in the population. Two national audits were conducted
in the UK in 1993 and 2007 respectively.1,2 In over a decade, the
crude overall mortality from AUGIB improved from 14 to 10%. The
age structure has not changed signiﬁcantly between the audits. In
the second audit, 63 percent of patients were older than 60 years.
Endoscopic therapy was performed in 24% (1172 of 4942) of
patients. The rate of surgery has diminished from 6.7 to 1.9%. In the
few who required surgery to stop bleeding, the mortality was 30%.
The present review summarizes the current literature on the
management of patients with AUGIB and speciﬁcally those with
nonvariceal causes, the commonest being bleeding from a peptic
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coagulopathy
Patients who present with overt signs of upper gastrointestinal
bleeding (melena or hematemesis with or without hypotension)
should be assessed early. In many, bleeding has stopped by the time
of presentation. The few with signs of ongoing bleeding should be
volume resuscitated. Blood should be administered to unstable
exsanguinating patients. In stable patients, clinicians should
consider transfusing when hemoglobin level drops below 7 g/dl
and aim for a level of around 8 g/dl. In patients with acute or
chronic cardiac diseases, a hemoglobin level of around 10 g/dl
should be the aim. There was evidence from the recent national UK
audit that red cell transfusion was associated with increased risk of
further bleeding across all risk categories as stratiﬁed by the Rockall
score. In patients with a score of 6 to 8, further bleeding occurred inng Special Administrative Region, China
tin, Hong Kong Special Administrative Region, China.
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(292/917) patients with red cell transfusion. Policy in blood trans-
fusion is now a subject of investigation in a large clinical trial in the
UK. The TriGGer trial led by a research group in Oxford is a multi-
center randomized controlled trial that compares liberal and
restrictive transfusion policies.3
In patients actively bleeding and unstable on warfarin, an
international normalized ratio (INR) <1.5 should be achieved
quickly with the treatment of fresh frozen plasma or prothrombin
complex. Low molecular weight heparin or heparin should be
discontinued and protamine should be administered to those with
a supra-therapeutic activated partial thromboplastin time and with
signs of ongoing bleeding. This should not delay endoscopy with
the objective to stop bleeding. The decision to reintroduce anti-
coagulation should be multidisciplinary, tailoring to individual
needs and balancing risk of further bleeding and withholding
anticoagulation therapy.
Although it is common sense to believe that aggressive resus-
citation improves outcome, the only evidence in the literature
comes from a comparative study using a historical cohort by Bar-
adarian et al, which showed that aggressive resuscitation (shorter
time to stable hemodynamics and to correct hematocrit >28 and
INR <1.8) led to reduced death (1/36 vs. 4/36) and myocardial
infarction (2/36 vs. 5/36).4
The use of prognostic scores in risk stratiﬁcation
It is recommended that patients should be risk stratiﬁed on their
presentations by the use of prognostic scores. The Rockall score is
a composite score that combines pre-endoscopy information as
well as ﬁndings at endoscopy.5 The score was derived from the ﬁrst
national UK audit to predict mortality from AUGIB. Blatchford and
colleagues from Glasgow subsequently published a clinical score,
based entirely on pre-endoscopy parameters.6 The Glasgow
Blatchford Score (GBS) was used to predict the need for interven-
tion, loosely deﬁned by the need for transfusion or endoscopic
therapy. GBS has been shown to be accurate in identifying low risk
patients (GBS<1) for early discharge. Its role in triaging patients for
be urgent out-of-hours endoscopy is less certain. We validated the
use of both Rockall and GBS in our local population with upper
gastrointestinal bleeding with the endpoint of predicting the need
for endoscopic therapy.7 In our setting, the pre-endoscopic Rockall
score was unable to predict such a need accurately. Although a high
GBS (>1) was sensitive (100%) in identifying all patients who
require endoscopic therapy, the speciﬁcity was only 6.7%. Many
out-of-hours endoscopies would be performed if one used GBS ¼ 1
as a cutoff point. While the GBS is a useful adjunct in deciding
whether to offer urgent endoscopy, we rely on the clinical signs of
ongoing bleeding (fresh hematemesis, shock with melena).
How soon should we scope patients with AUGIB?
It is generally believed that early endoscopy improves clinical
outcomes. This may well be true for individual patients with active
bleeding, but the strength of evidence in the literature to support
early endoscopy is not strong. Evidence in favor of early endoscopy
(usually deﬁned by endoscopy within 24 hours) comes only from
cohort studies. Cooper et al reviewed hospital records from of 909
consecutive patients from 13 hospitals and found that early
endoscopy was associated with reductions in recurrent bleeding,
surgery (odds ratio of 0.21) and hospitalization (–31%) in high-risk
patients.8 There have been three prospective randomized
controlled studies, each consisting of small number of patients.9–11
The risk description in these studies was poor. Obviously evenwith
a pooled analysis, these studies were not sufﬁciently powered todetect differences in recurrent bleeding, let alone mortality. It is
clear that across all risk categories, early endoscopy of patients
reduces hospitalization. Those at low risk can be considered for
early discharge. A clinical trial is ongoing at our hospital that
randomizes high-risk patients, deﬁned as those with a GBS of >11
and with stable hemodynamics to endoscopy within 6 hours of
admission or the next morning.
The use of proton pump inhibitors before endoscopy
We conducted a large double blind placebo controlled
randomized study in patients who presented with overt signs of
AUGIB.12 Patients who could initially be stabilized were random-
ized to receive a high dose proton pump inhibitor (PPI) infusion or
an equivalent placebo until endoscopy the next morning. The
proportion of bleeding peptic ulcers was 60%. We showed
a reduction in the need for endoscopic therapy in those who
received a PPI infusion (19.1% vs. 28.4%) for a mean of around 14
hours. There were fewer actively bleeding peptic ulcers in those
given PPI (12 of 187 vs. 28 of 190) coupled with more clean based
ulcers (120 of 180 vs. 90 of 190). PPI use led to fewer high risk
stigmata of bleeding. There was no difference in other clinical
outcomes. PPI use prior to endoscopy should, however, not be
misconstrued as a substitution for urgent endoscopy in those who
need it. In stable patients waiting for endoscopy, PPI should be
started early.
Stigmata of bleeding – which to treat?
In an early meta-analysis of 30 randomized controlled trials,
Cook et al provided convincing evidence that endoscopic therapy
reduced rates of further bleeding, surgery, and mortality in
bleeding peptic ulcers that were actively bleeding or exhibited
a nonbleeding visible vessel (A protuberant discoloration or
a sentinel clot).13 It is somewhat controversial whether to elevate
a clot overlying an ulcer base. Endoscopists differ in their vigor in
irrigating clots. In the literature, there are several deﬁnitions of an
adherent clot. Some endoscopists would irrigate an ulcer with
a thermal device for 5 minutes before declaring a clot ‘adherent’.
Others would go as far as guillotining or ‘cheese-wiring’ the clot
using a mini-snare. There have been two randomized controlled
studies that compared endoscopic to medical therapy alone in
ulcers with adherent clots. Both found a lower rebleeding rate
(1/21 vs. 12/35 and 0/15 vs. 6/17) with endoscopic therapy.14,15 In
a pooled analysis, Kahi et al summarized controlled trials on the
subject and concluded that endoscopic therapy after clot elevation
would reduce rate of further bleeding without impact on other
clinical outcomes.16 Endoscopists should, however, be wary that
a large subserosal artery may underlie a deep ulcer at high risk
positions such as the bulbar duodenum and angular notch of the
stomach. Clot elevation may provoke torrential bleeding. It may be
prudent to recourse to alternative therapy such as angiographic
embolization.
Optimal endoscopic therapy
It is now clear that endoscopic epinephrine injection should not
be used as a sole treatment. Calvet et al summarized 16 randomized
controlled trials of 1673 patients that compared epinephrine
injection alone to epinephrine injection followed by the addition of
a second treatment modality.17 The latter reduced the rate of
further bleeding from 18.4% to 10.6%, surgery from 11.3% to 7.6%,
and, importantly, mortality from 5.1% to 2.6%. In another meta-
analysis of 20 randomized trials that compared mono- to dual
therapy, injection alone was shown to be inferior to dual therapy.18
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therapy of injection plus either a mechanical or thermal treatment,
the outcome differences were not statistically different. The two
meta-analyses suggest that in the treatment of an actively bleeding
vessel, if we use preinjection of diluted epinephrine to volume
tamponade bleeding, a second treatment must follow to induce
thrombosis of the bleeding vessel. If a vessel can be clearly seen
without injection, one can either apply a thermal probe or
a mechanical device such as a hemoclip. Oftenwe use different and
often several treatment modalities if one should fail. The choice is
based on practical considerations. The application of clips can be
difﬁcult tangentially or with the scope in retroﬂexion in the difﬁcult
position of posterior bulbar duodenum and high lesser curvature.
We summarized clinical trials that compared the use of hemoclips
to thermal devices and found the rate of deﬁnitive hemostasis with
either modality identical (pooled odds ratio of 1). Both are equally
efﬁcacious as hemostatic treatment.19
The role of second-look endoscopy
It has been a common practice in certain parts of the world such
as Europe to perform second-look endoscopy the next morning in
patients who receive endoscopic hemostatic treatment. El Ouali
et al summarized results from four published articles and four
abstracts consisting of 938 patients on randomized controlled
study over the use of routine second-look endoscopy.20 Routine
second-look endoscopy signiﬁcantly reduced further bleeding (46/
472 vs. 77/466, P ¼ 0.002), surgery (9/303 vs. 20/304, P ¼ 0.04) but
not mortality. In a subgroup analysis removing two trials that
enrolled high-risk patients, the beneﬁts of routine second-look
endoscopy disappeared. Some of the trials included in the meta-
analysis predated the era of combination endoscopic treatment
and high dose PPI infusion. Their practices were considered not
contemporary. It is likely that the gain by performing second-look
endoscopy will diminish with a more aggressive index endoscopic
treatment and high dose PPI infusion. It is recommended that
second-look endoscopy should probably not be practiced routinely
but considered for high-risk patients. We adopt a liberal policy in
performing second look endoscopy in patients suspected of
developing recurrent bleeding. In an earlier randomized controlled
trial that compared the use of endoscopic retreatment to surgery in
patients who rebled clinically, we found a high success rate (75%) in
controlling bleeding with a second endoscopic attempt and
avoiding surgery in many patients.21
PPI therapy as an adjunct to endoscopic therapy – how much
and route of administration
Gastric neutrality is thought to be critical for clot stability. To
maintain gastric pH consistently above 7, a high dose PPI infusion is
required. Placebo controlled studies have conﬁrmed that acid
suppression can reduce rate of recurrent bleeding. The PUB study
was a placebo-controlled multicenter international study that
randomized 767 patients to receive either a high dose esomepra-
zole infusion or its placebo after endoscopic hemostasis to their
bleeding peptic ulcers.22 The use of PPI led to reduction in recurrent
bleeding in 72 hours (5.9% vs. 10.3%), further endoscopic treatment
(6.4% vs. 11.6%) and surgery (2.7% vs. 5.4%). The study reafﬁrms
ﬁndings of an earlier Cochrane systematic review that PPI as an
adjunct to endoscopic treatment reduces further bleeding and
improves outcomes.23
The optimal dose of PPI remains controversial. An Italian multi-
center study that compared head to head high-to low-dose PPI
found a similar rebleeding rate (11.8% and 8.1%) with either
regimen.24 A meta-analysis of clinical trials that compared a highdose PPI infusion to a low dose (deﬁned by 80 mg daily or below)
given either intravenously or orally suggested that a low dose
regime would be as efﬁcacious.25 The pooled analysis has to be
interpreted with caution. Several of the trials included consisted of
patients with low risk stigmata of bleeding and even clean-base
ulcers. The inclusion of such ulcers would dilute the potential
beneﬁt of a high dose regime. A fair comparison between low and
high dose PPI regimes should enroll consecutive patient including
those at high risk of rebleeding and death. Ideally the trial should be
of a double dummydouble blind design to test equivalence andwith
narrowmargins of accepted difference. More trials have emerged to
indicate a high dose is better than a low dose.26 No doubt the
controversy will continue. In the meantime, we have continued to
use a high dose regime particularly in high-risk patients.
Early discharge of ‘low-risk’ patients – is it really safe?
Patients with clean-base ulcers or ulcers with ﬂat pigments are
often discharged home following endoscopy. A low GBS (1) is
thought to be accurate to identify those at low risk for early
discharge. Cooper and colleagues27 recently examined outcomes of
9123 episodes of bleeding in patients with upper gastrointestinal
bleeding managed as in- or out-patients (38.4%) in a medicare
database. The overall 30 day mortality rate was 8% in the inpatient
group and 6.3% in the outpatient group. The high mortality asso-
ciated with an outpatient care is alarming. We retrospectively
analyzed causes of death in a cohort of 9375 patients with peptic
ulcer bleeding. The mortality rate was 6.2%, 79% of which were
nonbleeding related.28 This underlies the fact that clinicians are
often faced with old patients with signiﬁcant comorbid illnesses.
An episode of bleeding may herald another medical event such as a
cardiovascular accident. Patients are often required to be hospi-
talized for optimization of their medical conditions.
Angiographic embolization as an alternative to surgery after
failed endoscopic hemotasis
There have been improvements in interventional radiology
mostly in microcatheter techniques and new embolic agents.
Angiographic embolization should be the next treatment when
endoscopy therapy fails. Six retrospective studies compared
outcomes following transarterial embolization to surgery in
patients with uncontrolled bleeding at endoscopy and those who
rebled after initial control.29–34 Mortality following angiographic
embolization and surgery varied from 3–25.8% and
14–30%, respectively. In all studies, morbidities, mostly cardio-
vascular, were higher in those who received surgery. Complica-
tions directly related to angiographic embolization are uncommon
(from 0–10% in most series). These include duodenal ischemia and
secondary stenosis, gastric, hepatic or splenic infarction, groin
complications, and renal impairment. Our group is conducting
a prospective randomized controlled trial comparing the two
modalities as rescue procedures in patients with uncontrolled
bleeding during endoscopy. In addition, we advocate the use of
angiographic embolization to ulcers predicted at high risk of
rebleed after initial endoscopic hemostasis. Elmunzer et al
summarized the literature and found that some of the predictors
for failures of endoscopic treatment include large ulcer size,
posterior bulbar, and lesser gastric curvature ulcers in addition to
shock and presence of comorbid illnesses.35 The high-risk ulcers
located at bulbar duodenum and lesser curve can erode into
a subserosal artery from the gastro-duodenal or left gastric artery
complex. We believe that a prophylactic approach using angio-
graphic embolization may reduce signiﬁcantly risk of recurrent
bleeding and impact upon patient outcomes. We use a sandwich
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case of the gastro-duodenal artery, coils are deployed into the
conﬂuence between superior pancreatico-duodenal artery and
right gastro-epiploic artery. Gelfoam particles are then used to
pack the mid portion of the gastro-duodenal artery before coils are
again left in the proximal part of the artery. The technique blocks
off back bleeding from collaterals and reduces the risk of duodenal
ischemia as the use of coils is generally quite safe.
Testing for Helicobacter pylori – risk of false negatives
All patients with bleeding peptic ulcers should be tested for
Helicobacter pylori and treated for if present. A Cochrane meta-
analysis of 7 studies that included 578 patients that compared H.
pylori eradication to maintenance antisecretory therapy.36 The
mean percentage of rebleeding in H. pylori group was 2.9%
compared to that of 20% (odds ratio of 0.17) in the latter group.
Theremaybe false-negative results inH. pylori testing as blood in
the stomach may buffer acid. An alkaline milieu is less favorable for
H. pylori and its testing. Diagnostic tests forH. pylori in the setting of
an acute bleed yield lownegative predictive value between 0.45 and
0.75. There is a need for a repeat test at follow-up.
Patients who continue to require nonsteroidal anti-
inﬂammatory drugs
Among patients with an ulcer bleed, treatment either with
a COX-2 inhibitor or a NSAID plus a PPI is associated with
a signiﬁcant risk of recurrent ulcer bleed. Our group studied
patients who needed NSAIDs for arthritis and presented with
ulcer bleeding.37 They were tested H. pylori negative and then
randomized to receive 200 mg celecoxib daily or diclofenac and
a PPI. The probability of further bleeding in 6 months was 4.9% in
the celecoxib group and 6.4% in the diclofenac–PPI group. In
a subsequent trial, we randomized 273 such high-risk patients to
receive celecoxib or a celecoxib plus PPI.38 The combined treat-
ment abolished the risk of recurrent bleeding at 13-month follow-
up. The use of celecoxib was associated with a rebleeding risk of
8.9% in the same period. Patients at very high risk of recurrent
ulcer bleeding and yet requiring relief from their arthritis should
be given a COX-2 inhibitor and a PPI.
When to resume aspirin?
Aspirin should be restarted early in patients with a high
vascular thrombotic risk. We randomized 158 patients with
aspirin-induced ulcer bleeding to receive aspirin or its placebo
after endoscopic hemostasis and a PPI infusion for 3 days.39
Reintroduction of aspirin led a two-fold increase in recurrent
bleeding. The all-cause mortality increased signiﬁcantly when
aspirin was withdrawn (1.6% vs. 14.1%). The relative risk for
mortality was 1.7-fold greater in the no aspirin group. Cardiovas-
cular thrombotic complications often occur between 6 and 10 days
after withholding aspirin. Inhibited platelets circulate in the blood
for about 10 days. In patients whose ulcers harbor low risk stig-
mata, aspirin should be started soon after endoscopy. In almost all
cases, aspirin can be started after 3 days.
Clopidogrel versus aspirin and PPI for secondary prophylaxis
in a patient with a past bleed
The CAPRIE study published in 1996 prompted many clinicians
to switch patients from aspirin to clopidogrel.40 This was
a randomized study designed to compare aspirin 325 mg to clo-
pidogrel 75 mg taken daily in the prophylaxis against compositevascular event. A relative risk reduction of 8.7% was observed
associated with the use of clopidogrel (5.3 vs. 5.8% with mean
follow-up of 1.9 years in 19,185 patients). Two independent
randomized controlled studies from Hong Kong compared the use
of aspirin plus a PPI to clopidogrel alone in patients who had a prior
bleed and were H. pylori negative.41,42 Recurrent bleeding after 12
months was higher in the studies by Chan et al42 and Lai et al41 (13/
161 vs. 1/159 and 0/86 vs. 9/84, respectively). In a patient who has
had a bleed and continues to require an antiplatelet agent, aspirin
plus PPI appears to be a safer strategy.
A patient who needs dual antiplatelet therapy
Patients with drug eluting coronary stents require dual anti-
platelet therapy. Stent thrombosis is often fatal. Antiplatelet
therapy should be resumed as early as possible after an episode of
bleed especially those with low risk stigmata and in whom stents
were placed recently (within 6 months). Patients who continue to
require dual antiplatelet therapy and at risk of further bleeding
should be prescribed a PPI. There has been concern of drug
interaction between clopidogrel (a thienopyridine derivative that
blocks ADP receptors on platelets) and PPI. Both are metabolized
by CYP2C19 isoenzymes of the cytochrome P450 system in the
liver. The Clopidogrel and the Optimization of Gastrointestinal
Events Trial (COGENT) provided assurance that co-therapy with
PPI may be a better strategy.43 The trial randomized 3873 patients
to receive dual therapy with and without a PPI and found that the
gastrointestinal events were fewer with PPI (1.1% vs. 2.9% at 180
days). The cardiovascular event rate was 4.9% with PPI and 5.7%
with placebo. The prescription of a PPI less dependent than
CYP2C19 is probably desirable.
Can mortality from AUGIB be further reduced? The direction
forward
It is often said that despite of all advances, mortality fromAUGIV
has remained unchanged. This is untrue as evident from the
improved mortality ﬁgure between the two national UK Audits.
Further improvements may come in several areas. First, we are
seeing better strategies secondary prophylaxis against recurrent
bleeding. Second, patients should have easier access to care espe-
cially expertise in endoscopic therapy through better organization
of acute care. Third, recurrent bleeding and failed endoscopic
therapy predict a highmortality. This subgroup should be identiﬁed
early. Targeted care and early angiographic embolization to the
bleeding artery may be the way forward. The contemporary care of
patients with AUGIB should be multidisciplinary involving not only
endoscopists, interventional radiologists (very occasionally
surgeons) but also transfusion and ICU specialists in managing
coagulopathy and organ support. There will be new threats from
drugs such as Dabigatran and Rivaroxaban.
Conclusions
Endoscopic and PPI therapies are cornerstones to management
of AUGIB. The current debated issues are; whether early endoscopy
improves clinical outcomes and the paradoxical effect of blood
transfusion to recurrent bleeding. The management of patients on
antithrombotic drugs is complex. We lack clinical evidence and
management guidelines in these patients. Clinical research should
target patients predicted to fail endoscopic treatment.
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